Microneedle and iontophoresis mediated delivery of methotrexate into and across healthy and psoriatic skin.
Diseased skin
In vitro permeation testing
Iontophoresis
Microneedle
Psoriasis
Psoriatic skin
Topical and Transdermal delivery
Journal
International journal of pharmaceutics
ISSN: 1873-3476
Titre abrégé: Int J Pharm
Pays: Netherlands
ID NLM: 7804127
Informations de publication
Date de publication:
25 Apr 2022
25 Apr 2022
Historique:
received:
10
12
2021
revised:
13
03
2022
accepted:
18
03
2022
pubmed:
26
3
2022
medline:
14
4
2022
entrez:
25
3
2022
Statut:
ppublish
Résumé
Psoriasis is a condition of the skin which involves scales, dry patches, and inflammation. Methotrexate (logP: -1.8, MW:454.44 g/mol) is administered orally or intravenously to treat psoriasis. The first-pass metabolism and systemic toxicity can be avoided by administration via skin. Topical and transdermal delivery of methotrexate using iontophoresis and microneedles, alone and in combination was investigated using full-thickness healthy human skin. It is also equally relevant to evaluate the delivery into and across damaged/diseased skin. Hence, this study investigated the delivery of methotrexate using ex vivo healthy and psoriatic human skin to understand the effect of skin disease condition on delivery of methotrexate via skin. A lower resistance and a higher TEWL for psoriatic skin indicated damaged barrier function, while histology studies indicated epithelial hyperproliferation and elongated rete ridges. Using the optimized iontophoretic parameters, there was no significant difference in receptor delivery for psoriatic skin (39.51 ± 4.45 µg/sq.cm) as compared to healthy skin (43.15 ± 0.83 µg/sq.cm). However, methotrexate delivery into psoriatic skin (126.23 ± 24.65 µg/sq.cm) was significantly higher as compared to healthy skin (12.02 ± 4.89 µg/sq.cm). Thus, significantly higher total delivery was observed from psoriatic skin than healthy skin.
Identifiants
pubmed: 35331833
pii: S0378-5173(22)00248-4
doi: 10.1016/j.ijpharm.2022.121693
pmc: PMC9022631
mid: NIHMS1792297
pii:
doi:
Substances chimiques
Methotrexate
YL5FZ2Y5U1
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
121693Subventions
Organisme : FDA HHS
ID : R44 FD005345
Pays : United States
Organisme : NIH HHS
ID : U42 OD011158
Pays : United States
Informations de copyright
Copyright © 2022 Elsevier B.V. All rights reserved.
Références
Ther Deliv. 2021 Feb;12(2):133-144
pubmed: 33496196
Drug Deliv. 2008 Sep;15(7):437-42
pubmed: 18712621
J Am Acad Dermatol. 1983 May;8(5):645-7
pubmed: 6863620
Autoimmun Rev. 2014 Apr-May;13(4-5):490-5
pubmed: 24434359
Pharmaceutics. 2020 May 21;12(5):
pubmed: 32455797
Toxicol In Vitro. 2018 Sep;51:129-135
pubmed: 29698667
J Clin Aesthet Dermatol. 2016 Apr;9(4 Suppl 1):S2-S8
pubmed: 28936279
Curr Probl Dermatol. 2018;54:108-114
pubmed: 30130779
Skin Pharmacol Physiol. 2011;24(1):2-9
pubmed: 20588085
Int J Pharm. 2020 Aug 30;586:119584
pubmed: 32603836
Eur J Pharm Sci. 2020 Sep 1;152:105469
pubmed: 32679177
Int J Dermatol. 2003 Feb;42(2):157-9
pubmed: 12709009
Skin Res Technol. 2000 Nov;6(4):230-238
pubmed: 11428962
J Pharm Pharmacol. 2008 Jan;60(1):27-33
pubmed: 18088502
Pharmaceutics. 2018 Aug 05;10(3):
pubmed: 30081603
Expert Opin Drug Deliv. 2009 Apr;6(4):343-54
pubmed: 19348604
Skin Res Technol. 2017 Feb;23(1):41-47
pubmed: 27270565
Pharmaceutics. 2020 Mar 01;12(3):
pubmed: 32121515
Eur J Pharm Sci. 2021 Dec 1;167:105924
pubmed: 34289340
Drug Deliv Transl Res. 2015 Aug;5(4):407-23
pubmed: 26069156
Pharm Res. 2018 Feb 21;35(3):68
pubmed: 29468316
Int J Mol Sci. 2019 Mar 23;20(6):
pubmed: 30909615
Pharmaceutics. 2014 Dec 22;6(4):663-71
pubmed: 25533309
Drugs. 1990 Nov;40(5):697-712
pubmed: 2292232